Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin 1 held steady at 27%. Reported revenue in DKK ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging quarter in Wound & T ...

Coloplast A/S reported its second-quarter earnings for fiscal year 2026, revealing an earnings per share (EPS) of 6.19 DKK, surpassing the forecast of 5.98 DKK. Revenue stood at 7.08 billion DKK, in ...

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

The contract is awarded for products that bring improvement to the healthcare industry.Coloplast, a global medical device company and market ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...